Business Context and Reporting Period
This Form 8-K is filed by Bellevue Life Sciences Acquisition Corp. (BLAC), a Special Purpose Acquisition Company (SPAC), for the event date of June 23, 2024. The filing reports the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the appointment of Mr. Sang Hyun Kim as a director, effective immediately. He was appointed to fill vacancies on the following committees created by recent resignations:
- Audit Committee: Filling the vacancy left by Inchul Chung.
- Compensation Committee: Filling the vacancy left by Mr. Radclyffe Roberts.
- M&A Committee: Filling the vacancy left by Mr. Radclyffe Roberts.
Mr. Kim brings extensive experience in legal and investment sectors, including roles at Samsung Group and Korea Daesung Asset Management Co., Ltd. The Board has determined he meets the standards for an independent director under Nasdaq rules.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies are disclosed in this report other than the standard governance transition. Mr. Kim will not receive compensation for his services as a director.
Investor Verification Checklist
- Verify the independence status of Mr. Sang Hyun Kim under Nasdaq listing rules.
- Review the previously filed June 13, 2024 Form 8-K for details on the resignations of Inchul Chung and Radclyffe Roberts.
- Confirm the terms of the Letter Agreement and Indemnity Agreement referenced in the filing (Exhibits 10.1 and 10.6 of the April 17, 2024 Form 10-K).
- Monitor future filings for any updates on the SPAC's merger target or liquidation timeline, as this filing does not address deal progress.